Pyridostigmine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Pyridostigmine: Autoimmune disease of peripheral nervous system
One-Sentence Summary
Pyridostigmine is an acetylcholinesterase inhibitor originally used to treat myasthenia gravis and related neuromuscular junction disease. The TxGNN model predicts it may be effective for autoimmune disease of peripheral nervous system. Currently there are no registered clinical trials and 3 publications (one review, one case report and one cohort study) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Autoimmune disease of peripheral nervous system |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 4 of 4) |
| Number of DINs | 4 (marketed: 4) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, pyridostigmine is a reversible acetylcholinesterase inhibitor. By slowing the breakdown of acetylcholine, it raises acetylcholine levels at the neuromuscular junction. This is the established symptomatic mechanism in myasthenia gravis.
Thymic hyperplasia is a common feature of myasthenia gravis with acetylcholine receptor (AChR) antibodies. The predicted indication is therefore a subtype of the approved indication, so this is not true repurposing. The supporting literature is observational: a case of MuSK-positive MG with thymic hyperplasia and a cohort on thymectomy outcomes. None tests pyridostigmine specifically in this subgroup.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25683765 | 2015 | Cohort | Journal of Neurology | Two-year outcomes of thymectomy in 39 patients with non-thymomatous, AChR-antibody-positive late-onset MG |
| 34225443 | 2021 | Review | Molecular Medicine Reports | Genomic, phenotypic and epigenetic insights into MG pathology and autoimmunity |
| 18053719 | 2008 | Case report | Neuromuscular Disorders | MuSK-positive MG with thymus hyperplasia presenting with dropped head syndrome |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00869953 | MESTINON-SR | Not listed | Not listed |
| 00869961 | MESTINON | Not listed | Not listed |
| 02495643 | RIVA-PYRIDOSTIGMINE | Not listed | Not listed |
| 02508362 | JAMP PYRIDOSTIGMINE BROMIDE | Not listed | Not listed |
All four are valid single-ingredient products.
Safety Considerations
- Contraindication-related diseases (from the knowledge graph, not label text): kidney disease, pyoureter, asthma (including intrinsic and allergic asthma) and urinary tract obstruction.
- Drug Interactions: 78 interactions were identified. The 20 listed in the data compiled for this report are all rated Moderate. They include:
- Corticosteroids: hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone
- Anticholinergics and antispasmodics: atropine, scopolamine, hyoscyamine, glycopyrronium, dicyclomine, propantheline, trospium, methscopolamine, clidinium, mepenzolate
- Aminoglycosides: neomycin, kanamycin, paromomycin
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Pyridostigmine is already marketed in Canada and is a standard symptomatic treatment for myasthenia gravis. The predicted indication is a subtype of that use, and the pyridostigmine-specific evidence for this subgroup is observational only. No trials are registered.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, which are currently missing
- Mechanism of action data from DrugBank
- Dosage form and approved indication details for the four Canadian licences
- Review of the knowledge-graph contraindications (asthma, urinary tract obstruction, kidney disease) in the target patient group
- Attention to MuSK-positive MG, where cholinesterase inhibitors may respond poorly or worsen symptoms
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.